Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Translation of Cardiac Myosin Activation With 2-Deoxy-ATP to Treat Heart Failure Via an Experimental Ribonucleotide Reductase-Based Gene Therapy. Local targets link to admitted publications; unresolved targets remain external evidence.
A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure
10.1056/nejm199812173392503 · 1998 · External reference
Low-dose enoximone improves exercise capacity in chronic heart failure
10.1016/s0735-1097(00)00759-2 · 2000 · External reference
Inotropes
10.1016/j.jacc.2014.01.016 · 2014 · External reference
Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: multicenter automatic defibrillator implantation trial: cardiac resynchronization therapy
10.1161/circulationaha.110.955039 · 2010 · External reference
Reverse remodeling with left ventricular assist devices: a review of clinical, cellular, and molecular effects
10.1161/circheartfailure.110.959684 · 2011 · External reference
Gene therapy for heart failure
10.1161/circresaha.111.252981 · 2012 · External reference
Heart failure gene therapy: the path to clinical practice
10.1161/circresaha.113.300269 · 2013 · External reference
Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial
10.1016/s0140-6736(16)00082-9 · 2016 · External reference
Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial
10.1093/eurheartj/ehv254 · 2015 · External reference
Intracoronary gene transfer of adenylyl cyclase 6 in patients with heart failure: a randomized clinical trial
10.1001/jamacardio.2016.0008 · 2016 · External reference
A novel approach to improve cardiac performance: cardiac myosin activators
10.1007/s10741-009-9135-0 · 2009 · External reference
Cardiac myosin activation: a potential therapeutic approach for systolic heart failure
10.1126/science.1200113 · 2011 · External reference
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial
10.1016/s0140-6736(11)61126-4 · 2011 · External reference
Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina
2015 · External reference
Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study
10.1016/s0140-6736(11)61219-1 · 2011 · External reference
Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): A phase 2, pharmacokinetic, randomsed, placebo-controlled trial
10.1016/s0140-6736(16)32049-9 · 2016 · External reference
Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: the ATOMIC-AHF study
10.1016/j.jacc.2016.01.031 · 2016 · External reference
Molecular cloning of the cDNA for a mutant mouse ribonucleotide reductase M1 that produces a dominant mutator phenotype in mammalian cells
1988 · External reference
The structural basis for the allosteric regulation of ribonucleotide reductase
10.1016/b978-0-12-386931-9.00014-3 · 2013 · External reference
Upregulation of cardiomyocyte ribonucleotide reductase increases intracellular 2 deoxy-ATP, contractility, and relaxation
10.1016/j.yjmcc.2011.08.026 · 2011 · External reference
ATP analogs and muscle contraction: mechanics and kinetics of nucleoside triphosphate binding and hydrolysis
10.1016/s0006-3495(98)78012-9 · 1998 · External reference
Calcium regulation of tension redevelopment kinetics with 2-deoxy-ATP or low [ATP] in rabbit skeletal muscle
10.1016/s0006-3495(98)77907-x · 1998 · External reference
The effect of ATP analogs on posthydrolytic and force development steps in skinned skeletal muscle fibers
10.1016/s0006-3495(98)78013-0 · 1998 · External reference
2-Deoxy-ATP enhances contractility of rat cardiac muscle
10.1161/01.res.86.12.1211 · 2000 · External reference
Cross-bridge versus thin filament contributions to the level and rate of force development in cardiac muscle
10.1529/biophysj.103.039123 · 2004 · External reference
Positive inotropic effects of low dATP/ATP ratios on mechanics and kinetics of porcine cardiac muscle
10.1529/biophysj.105.079061 · 2006 · External reference
Increased intracellular [dATP] enhances cardiac contraction in embryonic chick cardiomyocytes
10.1002/jcb.21780 · 2008 · External reference
Refueling the heart: using 2-deoxy-ATP to enhance cardiac contractility
10.1016/j.yjmcc.2011.09.023 · 2011 · External reference
2-Deoxyadenosine triphosphate restores the contractile function of cardiac myofibril from adult dogs with naturally occurring dilated cardiomyopathy
10.1152/ajpheart.00530.2015 · 2016 · External reference
2-Deoxy adenosine triphosphate improves contraction in human end-stage heart failure
10.1016/j.yjmcc.2014.12.002 · 2015 · External reference
Transgenic overexpression of ribonucleotide reductase improves cardiac performance
10.1073/pnas.1220693110 · 2013 · External reference
X-ray structure of the magnesium(II).ADP.vanadate complex of the Dictyostelium discoideum myosin motor domain to 1.9 A resolution
10.1021/bi952633+ · 1996 · External reference
Cardiac length dependence of force and force redevelopment kinetics with altered cross-bridge cycling
10.1529/biophysj.103.039131 · 2004 · External reference
2-Deoxy-ATP enhances multiple kinetic parameters to improve cardiac function
10.1016/j.bpj.2015.11.1128 · 2016 · External reference
Structural basis for drug-induced allosteric changes to human β-cardiac myosin motor activity
10.1038/ncomms8974 · 2015 · External reference
Cell-based delivery of dATP via gap junctions enhances cardiac contractility
10.1016/j.yjmcc.2014.04.010 · 2014 · External reference
Thin filament incorporation of an engineered cardiac troponin C variant (L48Q) enhances contractility in intact cardiomyocytes from healthy and infarcted hearts
10.1016/j.yjmcc.2014.03.015 · 2014 · External reference
AAV6-mediated cardiac-specific overexpression of ribonucleotide reductase enhances myocardial contractility
10.1038/mt.2015.176 · 2016 · External reference
Large animal models of heart failure: a critical link in the translation of basic science to clinical practice
10.1161/circheartfailure.108.814459 · 2009 · External reference
Cardiac gene therapy in large animals: bridge from bench to bedside
10.1038/gt.2012.3 · 2012 · External reference
Ribonucleotide reductase-mediated increase in dATP improves cardiac performance via myosin activation in a large animal model of heart failure
10.1002/ejhf.270 · 2015 · External reference
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond
10.1007/s10741-009-9153-y · 2009 · External reference
Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo
10.1038/sj.gt.3302895 · 2007 · External reference
Heparin-binding correlates with increased efficiency of AAV1- and AAV6-mediated transduction of striated muscle, but negatively impacts CNS transduction
10.1038/gt.2012.60 · 2013 · External reference
Transendocardial delivery of AAV6 results in highly efficient and global cardiac gene transfer in rhesus macaques
10.1089/hum.2011.042 · 2011 · External reference
